BACKGROUND: The purpose of this study was to identify mechanisms of innate resistance to an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, erlotinib, in a panel of head and neck squamous cell carcinoma (HNSCC) cell lines. Specifically, we analyzed the role of HRAS mutations in erlotinib resistance. METHODS: Erlotinib sensitivity was determined by methyl thiazolyl-tetrazolium (MTT) assays. Molecular signaling pathways and somatic mutations were examined. Changes in sensitivity after modulation of HRAS expression were evaluated. RESULTS: All 7 cell lines were wild-type for EGFR and KRAS regardless of erlotinib sensitivity; however, 1 erlotinib-resistant cell line (HN31) harbored an HRAS G12D mutation. Downregulation of HRAS expression by small interfering RNA (siRNA) or short hairpin RNA (shRNA) in HN31 led to increased erlotinib sensitivity in vitro and in vivo. Transfection of activating HRAS-mutant (G12D and G12V) constructs into erlotinib-sensitive cell lines made them more resistant to erlotinib. CONCLUSION: Activating HRAS mutations can confer erlotinib resistance in an HRAS mutant HNSCC cell line.
BACKGROUND: The purpose of this study was to identify mechanisms of innate resistance to an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, erlotinib, in a panel of head and neck squamous cell carcinoma (HNSCC) cell lines. Specifically, we analyzed the role of HRAS mutations in erlotinib resistance. METHODS:Erlotinib sensitivity was determined by methyl thiazolyl-tetrazolium (MTT) assays. Molecular signaling pathways and somatic mutations were examined. Changes in sensitivity after modulation of HRAS expression were evaluated. RESULTS: All 7 cell lines were wild-type for EGFR and KRAS regardless of erlotinib sensitivity; however, 1 erlotinib-resistant cell line (HN31) harbored an HRASG12D mutation. Downregulation of HRAS expression by small interfering RNA (siRNA) or short hairpin RNA (shRNA) in HN31 led to increased erlotinib sensitivity in vitro and in vivo. Transfection of activating HRAS-mutant (G12D and G12V) constructs into erlotinib-sensitive cell lines made them more resistant to erlotinib. CONCLUSION: Activating HRAS mutations can confer erlotinib resistance in an HRAS mutant HNSCC cell line.
Authors: S A Forbes; G Bhamra; S Bamford; E Dawson; C Kok; J Clements; A Menzies; J W Teague; P A Futreal; M R Stratton Journal: Curr Protoc Hum Genet Date: 2008-04
Authors: P Rodriguez-Viciana; P H Warne; R Dhand; B Vanhaesebroeck; I Gout; M J Fry; M D Waterfield; J Downward Journal: Nature Date: 1994-08-18 Impact factor: 49.962
Authors: William Pao; Theresa Y Wang; Gregory J Riely; Vincent A Miller; Qiulu Pan; Marc Ladanyi; Maureen F Zakowski; Robert T Heelan; Mark G Kris; Harold E Varmus Journal: PLoS Med Date: 2005-01-25 Impact factor: 11.069
Authors: Bruno Bockorny; Maria Rusan; Wankun Chen; Rachel G Liao; Yvonne Li; Federica Piccioni; Jun Wang; Li Tan; Aaron R Thorner; Tianxia Li; Yanxi Zhang; Changhong Miao; Therese Ovesen; Geoffrey I Shapiro; David J Kwiatkowski; Nathanael S Gray; Matthew Meyerson; Peter S Hammerman; Adam J Bass Journal: Mol Cancer Ther Date: 2018-04-13 Impact factor: 6.261
Authors: Eliezer M Van Allen; Vivian W Y Lui; Ann Marie Egloff; Eva M Goetz; Hua Li; Jonas T Johnson; Umamaheswar Duvvuri; Julie E Bauman; Nicolas Stransky; Yan Zeng; Breean R Gilbert; Kelsey P Pendleton; Lin Wang; Simion Chiosea; Carrie Sougnez; Nikhil Wagle; Fan Zhang; Yu Du; David Close; Paul A Johnston; Aaron McKenna; Scott L Carter; Todd R Golub; Gad Getz; Gordon B Mills; Levi A Garraway; Jennifer R Grandis Journal: JAMA Oncol Date: 2015-05 Impact factor: 31.777
Authors: Chang Xu; Olga Nikolova; Ryan S Basom; Ryan M Mitchell; Reid Shaw; Russell D Moser; Heuijoon Park; Kay E Gurley; Michael C Kao; Carlos L Green; Franz X Schaub; Robert L Diaz; Hallie A Swan; In S Jang; Justin Guinney; Vijayakrishna K Gadi; Adam A Margolin; Carla Grandori; Christopher J Kemp; Eduardo Méndez Journal: Clin Cancer Res Date: 2018-03-29 Impact factor: 12.531
Authors: Jewon Jung; Kwang-Jin Cho; Ali K Naji; Kristen N Clemons; Ching On Wong; Mariana Villanueva; Steven Gregory; Nicholas E Karagas; Lingxiao Tan; Hong Liang; Morgan A Rousseau; Kelly M Tomasevich; Andrew G Sikora; Ilya Levental; Dharini van der Hoeven; Yong Zhou; John F Hancock; Kartik Venkatachalam Journal: EMBO Rep Date: 2019-02-20 Impact factor: 8.807
Authors: Sehrish Javaid; Antje Schaefer; Craig M Goodwin; Victoria V Nguyen; Frances L Massey; Mariaelena Pierobon; Da'Jhnae Gambrell-Sanders; Andrew M Waters; Kathryn N Lambert; J Nathaniel Diehl; G Aaron Hobbs; Kris C Wood; Emanuel F Petricoin; Channing J Der; Adrienne D Cox Journal: Mol Cancer Ther Date: 2022-05-04 Impact factor: 6.009
Authors: Nabil F Saba; Zhuo Gerogia Chen; Missak Haigentz; Paolo Bossi; Alessandra Rinaldo; Juan P Rodrigo; Antti A Mäkitie; Robert P Takes; Primoz Strojan; Jan B Vermorken; Alfio Ferlito Journal: Mol Cancer Ther Date: 2019-11 Impact factor: 6.261